RE: Bermuda 2811813 Mar 2020 10:35
I agree Chester .. the trials are one route, but we have others, and the Labs at Scancell are still busy on TCR, Karolinska, other Immunobody programs, other moditope , Modi2 and possibly 3 programs still in development ..
the Cronovirus may hinder, but the IP is still being advanced in the background that as yet has not been quantified by the market.
scancell will not suffer like the general economy because we don't trade. However we are not behaving like Inovio . seems every virus that appears, out pops Dr Kim with his 3 hour solution .. cap in hand. ... jump in the SP but a slow decline after when in reality they can't deliver ... failed programs galore ...squandering $500m on R and D ....
we have the correct model .. design it build it, test it and improve it ... before you enter trial .. The Avidmab development by the university followed exactly the same protocols that has advanced Immunobody and Moditope ... the collaborations that followed based on that science have shown potential commercial interest to others ... why ? because Lindy added the magic "high Avidity"
tick tock